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a b s t r a c t
Human epidermal growth factor receptor 2 (HER2) is a breast cancer biomarker that plays a major role in
promoting breast cancer cell proliferation and malignant growth. The extracellular domain (ECD) of
HER2 can be shed into the blood stream and its concentration is measurable in the serum fraction of
blood. In this work an electrochemical immunosensor for the analysis of HER2 ECD in human serum
samples was developed. To achieve this goal a screen-printed carbon electrode, modified with gold
nanoparticles, was used as transducer surface. A sandwich immunoassay, using two monoclonal
antibodies, was employed and the detection of the antibody–antigen interaction was performed through
the analysis of an enzymatic reaction product by linear sweep voltammetry. Using the optimized
experimental conditions the calibration curve (ip vs. log[HER2 ECD]) was established between 15 and
100 ng/mL and a limit of detection (LOD) of 4.4 ng/mL was achieved. These results indicate that the
developed immunosensor could be a promising tool in breast cancer diagnostics, patient follow-up and
monitoring of metastatic breast cancer since it allows quantification in a useful concentration range and
has an LOD below the established cut-off value (15 ng/mL).
1. Introduction
Based on data published by the World Health Organization, in
2008 breast cancer was the most frequent cause of cancer death in
women in both developing and developed regions. Incidence rates
are high in developed regions of the world (except Japan) and low
in most of the developing regions [1]. The higher incidence of
breast cancer in developed countries has been tempered by
reductions in mortality, largely attributable to mammographic
screening programs and advances in adjuvant therapy [2]. How-
ever, mammography screening has moderate sensitivity and
specificity and a low positive-predictive value in younger women.
Therefore, research has been conducted to identify the critical
biochemical changes in cancer and has led to advances in its
detection and treatment [3]. The detection of tumor markers has a
major importance for the diagnosis of the onset of breast cancer
[4]. Tumor markers are substances that can be found in the body
when cancer is present [5,6]. The biomarkers found in biological
fluids, blood in particular, apparently hold the best promise for the
development of screening assays [4]. A simple blood test that
could detect these cancers in their earliest stages could prevent
the deaths of millions of people and reduce the suffering of
patients and their families and the cost to society. The amount
of suggested biomarkers of breast cancer is ever-increasing, but
many of them are without clinical value. The established biomar-
kers include tissue markers, such as estrogen and progesterone
receptors and the human epidermal growth factor receptor 2
(HER2), and circulating markers, such as carcinoembryonic antigen
(CEA) and cancer antigen 15-3 (CA 15-3). Circulating tumor cells
are emerging biomarkers that have potential to become clinically
useful [2,7].
Regarding HER2, this receptor plays a major role in promoting
breast cancer cell proliferation and malignant growth [7]. The
HER2 gene expresses a transmembrane protein that is over-
expressed in approximately 15–30% of breast cancers [8–12].
Breast cancers associated with HER2 over-expression have an
accelerated growth and recurrence rate, and are associated with
decreased overall patient survival [12]. HER2 is a 185 kDa protein
and has three domains: an extracellular domain (ECD), a trans-
membrane region, and an intracellular tyrosine kinase domain
[10–12]. As many other membrane-anchored proteins, HER2 can
release its ECD into the circulation through a proteolytic
mechanism [10]. The concentration of HER2 ECD is measurable in
the serum fraction of blood and is therefore a potential and
clinically relevant marker for breast cancer [10]. The serum test,
which can be included in routine blood analysis, is noninvasive
and avoids the use of tissue (obtained by biopsy) which is
necessary for the established diagnostic methods (immunohisto-
chemistry (IHC) and fluorescent in situ hybridization (FISH)) for
the assessment of HER2 status. Furthermore, the IHC and FISH
methods only provide semi-qualitative results, separating patients
into HER2-positive and HER2-negative groups [13], whereas a
serum test provides quantitative results. An elevated HER2 ECD
serum level, which is more frequently observed in metastatic
breast cancer, is defined as Z15 ng/mL and was detected by a
Food and Drug Administration (FDA)-approved enzyme-linked
immunosorbent assay (ELISA) in up to 45% of metastasized breast
cancer patients [8,12]. Although the currently approved cut-off
value is 15 ng/mL, moderate increase (50 ng/mL) has also been
described in the absence of cancer [10] and other cut-off values
have been suggested [12]. The major advantage of a HER2 ECD
serum test, besides its diagnostic value, is the possibility of patient
follow-up and the monitoring of (metastatic) breast cancer, which
is of critical importance in the choice of the HER2-targeted
therapy. IHC and FISH are not commonly used for this purpose
because of the location of the metastases and the costs of biopsies.
Serum HER2 ECD concentrations are mostly assessed by ELISA-
based methods [12]. However, their lack of sensitivity and selectivity
and high detection limits highlights the need for ultrasensitive
immunological tests [12]. To overcome some of these problems,
electrochemical immunosensors could be adequate alternatives
because of their high selectivity and sensitivity which allows early
detection of many diseases. The instrumentation needed to operate
and analyze the results obtained by these biosensors has been reduced
to pocket-size dimensions, which make them ideal for the incorporat-
ing in point-of-care devices.
To date two electrochemical immunosensing methods for the
analysis of HER2 have been published [14,15]. Mucelli et al. [14]
used nanoelectrode ensembles as the transducer and a sandwich
immunoassay for the detection of HER2 in diluted cell lysates and
tumor lysates. The lowest concentration they analyzed was 40 ng/
mL. Al-Khafaji et al. [15] applied antibody-functionalized magnetic
beads in combination with a screen-printed carbon electrode. The
detection limit of the used sandwich immunoassay was 6 ng/mL.
In the present work a novel electrochemical immunosensor for
the quantification of HER2 ECD in serumwas developed by using a
gold nanoparticle-modified screen-printed carbon electrode as
transducer. Monoclonal anti-human-HER2 antibodies were immobi-
lized on the transducer surface and after incubation with a HER2
ECD-containing sample biotinylated monoclonal anti-human-HER2
detection antibodies were added. A streptavidin–alkaline phosphatase
conjugate was used to label the detection antibody. The detection of
the antibody–antigen interaction was possible by using an enzymatic
substrate (3-indoxyl phosphate, 3-IP) and silver ions. In the enzymatic
reaction silver ions are reduced to metallic silver which can be
analyzed by anodic stripping using linear sweep voltammetry.
2. Materials and methods
2.1. Materials and apparatus
All electrochemical procedures were performed using a potentio-
stat/galvanostat (Autolab PGSTAT101, Metrohm Autolab). The Autolab
system was controlled by the NOVA software package (v.1.9;
Metrohm Autolab). Single-use screen-printed carbon electrodes
(SPCE, DRP-110) and a specific connector (DRP-CAC) to interface
the SPCE and the potentiostat/galvanostat were supplied by Drop-
Sens. The SPCEs incorporate a conventional three-electrode config-
uration, printed on ceramic substrates (3.41.0 cm). Both the
working- (disk-shaped 4 mm diameter) and counter electrodes are
made of carbon inks, whereas the pseudoreference electrode and the
electric contacts are made of silver. A ring-shaped layer printed
around the working electrode constitutes the reservoir (50 μL) of the
electrochemical cell. SEM images were obtained at the “Centro de
Materiais da Universidade do Porto (CEMUP)” using FEI QUANTA 400
FEG / EDAX Pegasus X4M equipment.
2.2. Reagents
For the immunoassay an anti-human-HER2 ECD rabbit mono-
clonal capture antibody (Ab-capture), a recombinant HER2 ECD
protein (antigen), and an anti-human-HER2 ECD mouse mono-
clonal biotinylated detection antibody (Ab-detection) were used
(Sino Biological Inc.).
Tetrachloroauric(III) acid was obtained from Merck. Tris(hydroxy-
methyl)aminoethane, (Tris), streptavidin–alkaline phosphatase from
Streptomyces avidinii (S-AP), 3-indoxyl phosphate disodium salt, β-
casein from bovine milk, bovine serum albumin (BSA), human serum
(from male AB clotted whole blood), magnesium nitrate hexahydrate,
and nitric acid (Z65%) were purchased from Sigma-Aldrich. Silver
nitrate was supplied by Alfa Aesar.
Ultra-pure water (resistivity¼18.2 MΩ.cm) obtained from a
Millipore water purification system (Simplicity 185) was used
throughout the study.
Two Tris–HNO3 buffers were used in the experiments: Buffer 1:
0.1 M (pH 7.2) and Buffer 2: 0.1 M (pH 9.8)þ20 mM MgNO3. The
solutions of the reagents used in the immunoassay were prepared
Fig. 1. SEM images of the screen-printed carbon electrode modified with gold nanoparticles.
in Buffer 1, except for the 3-IP/Agþ solution which was prepared in
Buffer 2.
2.3. Electrode surface modification with gold nanoparticles
The modification of the SPCEs’ surfaces with gold nanoparticles
(AuNPs) was achieved through electrodeposition of gold from 40 mL of
a 0.1 mM [AuCl4] (in 0.1 M HCl) solution. The AuNPs were deposited
by applying a constant current (100 mA) for 240 s, followed by the
application of a constant potential (þ0.1 V) for 120 s [16]. The size of
the AuNPs obtained using this procedure is 32710 nm (Fig. 1).
2.4. Electrochemical immunoassay
After the nanostructuration of the SPCE, the biosensing phase of
the immunosensor was constructed as follows: (i) immobilization
through adsorption by placing 10 mL of a capture antibody solution
on the transducer’s surface (overnight incubation); (ii) surface
blocking with 40 mL of a β-casein solution (2%) (30 min). After both
steps the SPCE was washed with Buffer 1 and dried.
The immunoassay (Fig. 2) consisted of the following steps:
(i) incubation with the antigen (HER2 ECD) (40 mL; 1 h); (ii) addition
of 40 mL of a biotinylated detection antibody solution (1 h); (iii)
addition of 40 mL of an S-AP solution (1 h); (iv) addition of 40 mL of a
solution containing the enzymatic substrate (3-IP) (1.0 mM) and
silver ions (0.40 mM) (20 min) (v) detection of the analytical signal
by linear sweep voltammetry (potential scan: 0.03 to þ0.4 V; scan
rate: 0.05 V/s). This signal was obtained through the anodic stripping
of the enzymatically generated metallic silver [17]. After steps (i) and
(ii) the SPCE was washed with Buffer 1 and dried. After step (iii) the
SPCE washed with Buffer 2 and dried.
3. Results and discussion
3.1. Optimization of the electrochemical immunoassay
In the optimization of the S-AP concentration, four different
concentrations were used: 11010; 21010; 51010 and
1109 M. The obtained peak current intensities (ip; n¼3) are
presented in Fig. 3.
As can be observed in Fig. 3 the ip increases with the increase of
S-AP concentration for both the blank assays as well as the assays
in which the antigen was used. Furthermore, the precision of the
results decreases when the S-AP concentration is increased.
Therefore, an S-AP concentration of 21010 M was chosen for
the subsequent studies.
In order to reduce the analysis time the combination of several
steps of the immunoassay was studied by pre-incubating the
reagents before their placement on the SPCE. The tested alter-
natives were: (1) mixture of HER2 ECD with the detection anti-
body; (2) mixture of the detection antibody with S-AP; and
(3) mixture of HER2 ECD with the detection antibody and S-AP.
Fig. 2. Schematic representation of the immunoassay.
Fig. 3. Obtained ip (n¼3) by linear sweep voltammetry for different S-AP
concentrations (11010; 21010; 51010 and 1109 M). (Ab-capture
(50 μg/mL), casein (2%), HER2 ECD (0 (blank) and 300 ng/mL), Ab-detection (5 μg/
mL), 3-IP (1.0 mM) and Agþ (0.40 mM)).
Because of the relatively high signals obtained in the blank assays,
which impedes the detection of low HER2 ECD concentrations,
BSA (final concentration: 0.5%) was added to the mixtures to
reduce non-specific adsorption.
The alternatives (2) and (3) mentioned above were unsuccess-
ful because no stripping current (ip¼0) was observed. The
obtained peak current intensities (ip; n¼3) for a normal (no
previous mixing of reagents, but addition of BSA (0.5%) to the
HER2 ECD and Ab-detection solutions) and the alternative (1) assay
are presented in Fig. 4.
As can be seen in Fig. 4 the pre-incubation of the antigen with
the detection antibody resulted in a decrease of the blank signal
and an increase of the analyte/blank signal ratio when compared
to the ‘normal’ assay. This can be explained by the additional
washing step in the ‘normal’ assay which reduces the surface
blockage and increases non-specific adsorptions. The use of the
pre-incubation step (which is the combination of steps (i) and (ii)
of the immunoassay (see Section 2.4)) leads to a 1-h decrease of
the assay time (total time: 2 h/50 min) and was therefore used in
the subsequent studies. To evaluate the ideal incubation time of
the HER ECD-Ab-detection mixture, assays were performed by
mixing the reagents 5 min and 1 h before their placement on the
SPCE. No significant differences between the ip values were
obtained for both the blanks (Δip¼0.21 mA) as well as the assays
in which the antigen was used (Δip¼2.6 mA). A 5-min pre-
incubation time was selected for the next studies.
For the optimization of the Ab-capture and Ab-detection
concentrations assays using the following conditions were per-
formed: Ab-capture: 10, 25 and 50 mg/mL, casein: 2%, HER2 ECD: 0
(blank) and 150 ng/mL, Ab-detection: 0.1; 0.5 and 1 mg/mL, BSA:
0.5%, S-AP: 21010 M, 3-IP: 1.0 mM and Agþ: 0.40 mM.
In the majority of the assays an increase of the ip was observed
when the antibody concentrations were increased (Fig. 5). The
highest ip was obtained when the Ab-capture and Ab-detection
concentrations were 50 mg/mL and 1 mg/mL, respectively. These
concentrations were used for the analysis of HER2 ECD in
human serum.
3.2. Serum analysis
To establish the calibration curve for the analysis of HER2 ECD
in human serum, first the working range was evaluated by
analyzing HER2 ECD (15 to 150 ng/mL) in buffer solutions using
the optimized electrochemical immunoassay. A linear relationship
between ip and log[HER2 ECD] (ip¼(37.7472.90)log[HER2 ECD]
(18.3375.01), r¼0.991, n¼5) was established in the entire stu-
died range. The same concentrations were used for the analysis of
HER2 ECD in spiked human serum. In these experiments BSA was
not added to the mixture of HER2 ECD and Ab-detection to avoid
complete blockage of the transducer’s surface. Typical voltammo-
grams obtained in the analysis of the serum samples are presented
in Fig. 6a. A clear difference was observed between the ip of the
blank assay and the lowest antigen concentration (15 ng/mL),
which corresponds to the established cut-off value. The linear
range was established between 15 and 100 ng/mL HER2 ECD
(Fig. 6b).
Fig. 4. Obtained ip (n¼3) by linear sweep voltammetry for different assay strategies.
(Ab-capture (50 mg/mL), casein (2%), HER2 ECD (0 (blank) and 300 ng/mL), Ab-
detection (5 mg/mL), BSA (0.5%), S-AP (21010 M), 3-IP (1.0 mM) and Agþ
(0.40 mM).
Fig. 5. Obtained ip (n¼3) by linear sweep voltammetry for different concentrations of Ab-capture (10, 25 and 50 mg/mL) and Ab-detection (0.1; 0.5 and 1 mg/mL). (casein
(2%), HER2 ECD (0 (blank) and 150 ng/mL), BSA (0.5%), S-AP (21010 M), 3-IP (1.0 mM) and Agþ (0.40 mM)).
The slope of the calibration curve for the serum analysis was
slightly lower than the slope obtained in the analysis of aqueous
solutions, so the influence of the serum matrix is reduced. In
Table 1 several figures of merit [18,19] for the developed electro-
chemical immunoassay are indicated. The limit of detection was
calculated using the average blank signal plus three times the
standard deviation.
Based on the data presented in Table 1 it can be concluded that
the developed immunosensor presents a useful concentration
interval because it allows the quantification of the biomarker in
a relatively wide concentration range, which could allow the
evaluation of the patient’s response to therapy. For high HER2
ECD concentrations (outside the calibration interval) a simple
dilution of the sample with buffer will be sufficient. The limit of
detection for the analysis of HER2 ECD is well below the estab-
lished cut-off value (15 ng/mL), which allows the early diagnosis of
breast cancer associated with HER2 over-expression. The precision
of the method is also adequate since Vx0o5% and the average CV
for the spiked serum samples was 5.7%.
In comparison with the published electrochemical immunoassay
for serum HER2 ECD analysis [15], the analysis time of the developed
immunosensor in this work was slightly longer (720 min). However,
in the previous study the linear calibration curve was established
only between 0 and 15 ng/mL (n¼4), the LOD was 6 ng/mL and the
reproducibility for spiked serum samples in terms of CV was about
10%. Therefore, the developed immunosensor presents better perfor-
mance characteristics than the previously developed assay.
Currently two commercial and FDA-approved HER2 ECD serum
tests, both based on immunological sandwich assays, are available:
the Siemens Healthcare Diagnostics ADVIA Centaurs Serum HER-
2/neu test and the Oncogene Sciences HER-2/neu ELISA (Wilex
Inc.). The Siemens test is fully automated and presents a very short
analysis time (o10 min), a concentration range between 0.5 and
350 ng/mL and an LOD of 0.5 ng/mL. The reported CV is between
3.2 and 5.7%. The major drawback of this assay is the relatively
costly equipment necessary for the assay performance, which is
therefore not widely available. Here the Oncogene Sciences HER-
2/neu ELISA presents an alternative, but presents a narrower
concentration range (1.5–35 ng/mL), higher LOD (1.5 ng/mL) and
CV (1–17.7%), and a much longer analysis time (45 h/15 min). In
general, the performance characteristics of the immunosensor
developed in this work are similar to those of the commercial
tests. Therefore, the developed immunosensor could be a promis-
ing tool in breast cancer diagnostics, patient follow-up and
monitoring of metastatic breast cancer.
4. Conclusions
An electrochemical immunosensor for the analysis of HER2 ECD
in human serum was developed by using a gold nanoparticle-
modified screen-printed carbon electrode as transducer and a
sandwich immunoassay. The optimized analysis time was 2 h/
50 min. The calibration curve (ip vs log[HER2 ECD]) was established
between 15 and 100 ng/mL and a limit of detection of 4.4 ng/mL was
achieved. Like this, the developed electrochemical immunosensor
could be useful in the diagnostic and follow-up of (metastatic) breast
cancer patients. However, additional studies using blood samples
from healthy individuals and cancer patients should be conducted to
evaluate the sensor’s utility and validate its performance in clinical
settings.
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